Only hours after announcing a positive recommendation in Europe for terminal complement inhibitor Soliris (eculizumab) in atypical hemolytic uremic syndrome (aHUS), Alexion Pharmaceuticals Inc. won accelerated FDA approval for the drug in that indication Friday, marking what could be only the first label expansion across a host of orphan diseases.